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ORIGINAL ARTICLE
Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile
Acid Composition Depend on Localization of Murine Intestinal
Inﬂammation
Monika Rau, MD,* Bruno Stieger, PhD,† Maria J. Monte, PhD,‡ Johannes Schmitt, PhD,* Daniel Jahn, PhD,*
Isabelle Frey-Wagner, PhD,§ Tina Raselli,§ Jose J. G. Marin, PhD,‡ Beat Müllhaupt, MD,§
Gerhard Rogler, MD, PhD,§ and Andreas Geier, MD*,§
Background: Fibroblast growth factor (FGF) 15/19 is part of the gut-liver crosstalk accounting for bile acid (BA) metabolism regulation.
Dysregulation of ﬁbroblast growth factor 15/19 signaling is observed in different pathological conditions, for example, in gastrointestinal diseases such as
inﬂammatory bowel disease (IBD). To understand the molecular bases, we analyzed the enterohepatic regulation of Fgf15-mediated pathway in 2
different inﬂammatory bowel disease mouse models.
Methods: Target genes of the BA-farnesoid-X-receptor (Fxr)-Ffg15 axis were quantiﬁed by RT-PCR or western blotting in gut and liver of dextran
sulfate sodium (DSS)-treated and IL10(2/2) mice. Serum Fgf15 levels were analyzed by ELISA. Biliary and fecal BA composition was differentiated by
HPLC-MS/MS.
Results: Dextran sulfate sodium-treated mice with ileum-sparing colitis showed higher Fgf15 serum levels. In contrast, IL10(2/2) mice with ileitis had
a trend toward decreased Fgf15 serum levels compared with controls and increased expression of Asbt as a negative Fxr-target gene. In hepatic tissue of
both models, no histological changes, but higher interleukin 6 (IL-6) mRNA expression and down-regulation of Fxr and Cytochrom P450 7a1 mRNA
expression were observed. Fibroblast growth factor receptor 4 up-regulation was in line with higher Fgf15 serum levels in dextran sulfate sodium-treated
mice. A distinct fecal BA proﬁle was observed in both models with signiﬁcantly higher levels of taurine-conjugated BA in particular tauro-b-muricholic
acid in IL10(2/2) mice.
Conclusions: Ileum-sparing colitis is characterized by activation of Fxr-Fgf15 signaling with higher expression of Fxr-target gene Fgf15,
whereas ileal inﬂammation showed no signs of Fxr-Fgf15 activation. Abundance of BA such as T-b-MCA may be important for intestinal Fxr
activation in mice.
(Inﬂamm Bowel Dis 2016;22:2382–2389)
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E nterohepatic ﬁbroblast growth factor (FGF19) in humans andFgf15 in rodents is part of the gut-liver signaling axis and
regulates bile acid (BA), glucose and lipid homeostasis, and metab-
olism in different physiological and pathological conditions.1 Fibro-
blast growth factor (FGF) 15/19 is secreted from the enterocyte into
the portal circulation, reaches the liver as major target organ, and
binds to hepatic ﬁbroblast growth factor receptor 4 (Fgfr4).2
Ligand-receptor afﬁnity of FGF15/19 and Fgfr4 is furthermore
increased by the single-pass transmembrane protein b-Klotho,
which is abundantly expressed in liver tissue.3 Enterohepatic feed-
back regulation of BA homeostasis is coordinated by FGF15/
19-mediated activation of FGFR4, a receptor tyrosine kinase spe-
ciﬁc for FGF15/19 in the liver and contributes to down-regulation
of cytochrome P450 isoform 7A1 (CYP7A1) as the rate-limiting
enzyme for BA synthesis.4,5 Independent of this enterohepatic
FGF15/19 signaling, hepatic farnesoid X receptor (FXR) activation
per se inhibits CYP7A1 expression and thus BA synthesis via up-
regulation of small heterodimer partner (SHP).6,7 At the level of
gall bladder motility, FGF15/19 exerts further negative feedback
resulting in inhibition of bile release and hence decreasing the
amount on BAs reaching the duodenum.8
Enterohepatic circulation of BAs contributes to the main-
tenance of the body BA pool.9 In the ileum, BAs are reabsorbed
by the apical Na+-dependent BA transporter (ASBT) that is neg-
atively feedback regulated by BAs.10 In mice, Fxr activation by
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BAs in the enterocyte induces transcription of intestinal BA bind-
ing protein (Ibabp) and Fgf15.4,11
The gut-liver axis is in the focus of recent research of
intestinal and hepatic diseases particularly in diseases affecting
both organs such as inﬂammatory bowel disease (IBD). IBD
patients have a higher prevalence of cholestatic liver diseases such
as primary sclerosing cholangitis (PSC) affecting intrahepatic and
extrahepatic bile ducts. In two-thirds of patients, primary
sclerosing cholangitis is associated with IBD mainly ulcerative
colitis (UC).12 The etiology is still poorly understood and there are
no mechanistic explanations for the strong association between
primary sclerosing cholangitis and IBD to date.
Dextran sulfate sodium (DSS)-induced colitis is a well-
accepted and frequently used mouse model for IBD.13 Location
and degree of colitis in DSS-treated mice is dependent on different
factors, such as quantity and molecular weight of DSS, duration of
administration, and the mouse strain.14 Typically, inﬂammation is
limited to the large intestine with minor alterations in the small
bowel. In contrast, knockout mouse for interleukin 10 (IL10(2/2)),
which is another well-established IBD model, develops a continu-
ously increasing inﬂammation in the entire gastrointestinal tract
including the ileum.15
In our study, DSS-treated mice were investigated as a model
for pancolitis without affection the terminal ileum as frequently
observed in UC. IL10(2/2) mice was used as an additional IBD
model with an inﬂammation affecting the entire gastrointestinal
tract including the terminal ileum, which shares this characteristic
with Crohn’s disease (CD).
Because the overall functional effect of IBD on intestinal
FGF19 expression, hepatic FGFR4 signaling and BA homeostasis
are unknown to date, the present study aimed to analyze
qualitative changes in the fecal BA proﬁle, the enterohepatic
Fgf15/Fgfr4 signaling pathway, and the potential consequences
on BA pool composition in 2 different mouse models of IBD.
METHODS
Animals
C57-BL/6J-Fue female mice were housed according to the
Swiss animal protection ordinance and approved by the cantonal
veterinary ofﬁce in the University Hospital Zurich animal facility and
the local ethics committee. Access to drinking water was ad libitum.
Twelve mice (age 6–8 wk) were treated with 2% dextran sulfate
sodium (DSS; molecular weight 35,000–50,000) for 7 days in the
drinking water. Twelve mice in the control group (age 6–8 wk)
received normal drinking water for the same duration. Liver tissue,
small and large bowel, and serum and bile samples were harvested
together with stool samples at day 7 in the morning (2–4 hr after the
last meal) and immediately stored in liquid nitrogen.
BL6-IL10tmlCgn (IL10(2/2)) male mice (n ¼ 12) were
bred in the University Hospital Zurich animal facility after
approval by the local ethics committees and had access to drink-
ing water ad libitum. Animals were sacriﬁced after 6 to 12 months
after signs of inﬂammation in the gastrointestinal tract in form of
rectal prolapse became apparent.
Histology and Endoscopic Examination
Intestinal and hepatic tissue was immediately embedded in
parafﬁn and ﬁxed in 4% formalin. Sections of 3 mm were cut and
stained with hematoxylin and eosin according to standard pro-
tocol. Colonic and ileal sections were analyzed accordingly.
Endoscopy of the large bowel was performed as previously
described.16
RNA Extraction and Reverse
Transcription PCR
Total RNA was isolated from liver tissue and the ileum by
using RNeasy Mini Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. mRNA was reverse-transcribed using
the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Mannheim, Germany). Expression was normalized
against Hprt. Genes were analyzed by quantitative real-time
PCR with Fast SYBR Green Master Mix (Applied Biosystems)
on an Applied Biosystems 7900HT RT-PCR System. Primers
were designed by using Primer express 3.0 (Applied Biosystems)
and synthesized by MicroSynth AG (Balgach, Switzerland). Pri-
mers were used as previously published.17
Western Blot Analysis
Microsomal protein fractions were prepared from frozen liver
tissue. Protein samples were separated by SDS-PAGE and blotted
on nitrocellulose membranes. Antibody staining and immune
complexes detection were performed as previously described.17 Pri-
mary antibodies used in the study were directed against basolateral
Na+-dependent taurocholate cotransporting polypeptide (mNTCP18),
multidrug-resistance-associated protein 2 (mMRP219), bile salt
export pump (BSEP20), multidrug-resistance-associated protein 4
(mMRP4) (ab45602), and multidrug-resistance-associated protein
3 (mMRP3) (ab3375). Na/K-ATPase (ab7671-50) was used as
a loading control. Densitometric quantiﬁcation of western blots
was performed using Adobe Photoshop CS3.
Serum Analysis
Alanin-aminotransferase and bilirubin levels were mea-
sured in serum using a multiple biochemistry analyzer (Ektachem
DTSCII; Johnson & Johnson Inc., Rochester, NY). Serum ﬁbro-
blast growth factor 15 was quantiﬁed by ELISA Kit (E80154Mu;
Uscn Life Science, Wuhan, China).
Biliary and Fecal Bile Analysis by HPLC-MS/MS
Method
Bile and feces were collected during sacriﬁce. BAs in bile
were analyzed after dilution with methanol, without further
treatment. For fecal BA isolation, feces were solubilized in 50%
tert-butanol and incubated over night at 48C. After sonication at
maximal power for 1 minute, samples were centrifuged. Extracted
BAs were subsequently analyzed as described above.
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BAs were analyzed in an HPLC-MS/MS (6410 Triple Quad
LC/MS; Agilent Technologies, Santa Clara, CA) as previously
reported.21
Statistical Analysis
Statistical signiﬁcance was determined by Mann–Whitney
U test. P-values ,0.05 were considered as statistically signiﬁcant
(*,0.05, **,0.01, ***,0.001). Data represent the mean 6
SEM. Analyzes were performed with PASW Statistics 18.0.0,
(Chicago, IL) and GraphPad 5.01 (GraphPad Software Inc., CA).
RESULTS
DSS Treatment and IL-10 Deﬁciency Lead to
Different Inﬂammatory Phenotypes in the
Intestine Without Histological and
Biochemical Alterations of the Liver
DSS-treated mice showed inﬂammation in the entire colon
as demonstrated by colonoscopy and microscopic changes in
histology (Fig. 1A). DSS treatment caused a loss of crypt structure
and extensive inﬁltration reaching the lamina muscularis mucosae
and thickening of the mucosa with abundant edema in the colon.
Histological analysis of IL10(2/2) mice revealed overt inﬂamma-
tory changes in colon and in the ileum (Fig. 1A, B). Histological
score for inﬂammation and epithelial cell damage of the colon was
assessed as described previously.22 DSS-treated mice and IL10(2/2)
mice had signiﬁcantly increased histological score compared with
the control group with the highest score in the DSS group (see Fig.
1, Supplemental Digital Content 1, http://links.lww.com/IBD/
B315). Murine endoscopic index of colitis severity (MEICS) was
signiﬁcantly increased in DSS-treated mice. DSS-treated mice
further showed a signiﬁcant shortening of the colon (mean 6
SEM: 6.4 6 0.1 cm [DSS] versus 9.0 6 0.2 cm [control]; P ,
0.0001) and weight loss (mean 6 SEM: 27.6 6 1.3% [DSS]
versus 3.0 6 1.0% [control]; P , 0.0001) at the end of the DSS
treatment. In the control group, no colonic epithelial damage or
inﬁltration was found.
In both IBD mice models, gene expression in the ileum of
tumor necrosis factor-a (TNF-a) was investigated to better character-
ize the site of inﬂammation. In DSS-treated mice, the primary inﬂam-
matory site was limited to the colon, conﬁrmed by reduced TNF-
a expression in ileum compared with control. In contrast, IL10(2/2)
showed higher ileal TNF-a gene expression, which is in line with
inﬂammatory changes affecting also the small intestine (Fig. 1C).
No histological changes in the liver have been observed in
both DSS-treated and IL10(2/2) mice (Fig. 2). Liver function tests
in serum including alanin-aminotransferase, bilirubin, and BAs
were not elevated in DSS-treated mice (data not shown).
The Fxr-Fgf15 Pathway Is Differentially
Regulated in the Ileum of DSS-treated and
IL10(2/2) Mice
Functional consequences of intestinal inﬂammation on the
Fxr-Fgf15 pathway in the ileum, which is mainly involved in BA
signaling and absorption, were analyzed. Fgf15 mRNA expression
and Fgf15 protein levels in serum were analyzed in both mouse
models. mRNA expression of ileal Fgf15 and Fgf15 protein in serum
were increased in DSS-treated mice compared with controls (mRNA
mean 6 SEM: 256.3 6 55% of control, P , 0.05; protein mean 6
SEM: 622.8 6 119.7 pg/ml [DSS] versus 368.6 6 46.8 mg/dL
[control], P , 0.05). On mRNA level, no changes were observed
for IL10(2/2) mice, but signiﬁcantly lower Fgf15 serum levels were
measured (222.1 6 27.9 pg/ml [IL10(2/2)] versus 622.8 6 119.7
FIGURE 1. Endoscopic images and histological ﬁndings in DSS and IL10(2/2) mice. A, Representative images of colonoscopy and histology in
control mice without signs of inﬂammation and DSS-treated mice with macroscopic and microscopic signs of colitis. B, Colonic and ileal histology
of IL10(2/2) mice with signs of inﬂammation. C, Relative mRNA expression of TNF-a in ileum of control mice, DSS-treated mice, and IL10(2/2) mice
with highest TNF-a expression in IL10(2/2) mice. *P , 0.05, **P , 0.01, ***P , 0.001.
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pg/ml [DSS], P, 0.05) compared with DSS-treated mice and a trend
toward lower Fgf15 serum levels was observed even in comparison
with WT mice (Fig. 3A, B).
These ﬁndings suggested that intestinal inﬂammation not
including the ileum as observed in DSS-treated mice leads to
activation of Fxr-Fgf15 pathway, which is absent in IL10(2/2) mice.
Therefore, expression of further Fxr target genes was analyzed in
DSS-treated mice. In line with Fxr activation, no up-regulation of
the negative Fxr target gene Asbt was observed in DSS mice,
whereas higher expression of Asbt was seen in IL10(2/2) mice
(Fig. 3C).
Intestinal Inﬂammation Leads to
a Down-regulation of Hepatic Cyp7a1
and BA Transporter Genes
Interleukin 6 (IL-6) mRNA as a proinﬂammatory cytokine
was signiﬁcantly elevated in the liver of DSS-treated and IL10(2/2)
mice (mean 6 SEM: 324.8 6 99.8% [DSS] of controls; P , 0.05
and 463.5 6 67.1% [IL10(2/2)] of controls; P , 0.01), indicating
inﬂammatory changes at the molecular level despite the absence of
macroscopic and microscopic changes (Fig. 4A). Expression of
Fgfr4 mRNA was increased in DSS-treated mice (133.8 6 18.2%
of controls, P , 0.05) and decreased in IL10(2/2) mice (52.7 6
7.3% of controls, P , 0.01) (Fig. 4B). These changes are in line
with differences in Fgf15 serum levels in these mouse models.
Quantiﬁcation of BA target genes in hepatic tissue showed no
signiﬁcant change of Fxr expression in DSS-treated mice (84.9 6
11.1% of controls), but down-regulation of the rate-limiting enzyme
for BA synthesis, that is, Cyp7a1 (42.4 6 14.9% of controls, P ,
0.05), which is well in accordance with the observed increase in
Fgf15 and Fgfr4 expression. In IL10(2/2) mice, a decreased Fxr
expression (64.0 6 8.0% of controls, P , 0.001) and a reduction
in Cyp7a1 mRNA levels (32.7 6 4.2% of controls, P , 0.001) in
liver were observed (Fig. 4C, D).
Expression of genes involved in BA transport by hepatocytes
was mostly decreased in both mouse models as shown in Fig. 2,
FIGURE 2. Liver histology in DSS and IL10(2/2) mice. Microscopic no pathologic ﬁndings in control, DSS, and IL10(2/2) were observed.
FIGURE 3. Relative mRNA expression of target genes in ileum and Fgf15 serum levels. A, Signiﬁcant higher Fgf15 mRNA expression was observed
in DSS-treated mice in comparison with IL10(2/2) mice. B, Ffg15 serum levels were signiﬁcantly increased in DSS-treated mice compared with
control and IL10(2/2) mice. C, Asbt mRNA expression was signiﬁcantly increased in IL10(2/2) mice and no change was observed for DSS mice
compared with control mice. *P , 0.05, **P , 0.01, ***P , 0.001.
Inﬂamm Bowel Dis  Volume 22, Number 10, October 2016 Alterations in Enterohepatic Fgf15 Signaling in IBD
www.ibdjournal.org | 2385
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
Supplemental Digital Content 2, http://links.lww.com/IBD/B316.
Ntcp mRNA expression, as a principal BA transporter, was signif-
icantly lower in DSS-treated and IL10(2/2) mice (Ntcp: 60.6 6
7.4% [DSS] and 51.7 6 7.1% [IL10(2/2)] of controls, P , 0.01
and P , 0.001). Bsep mRNA expression was signiﬁcantly reduced
in DSS-treated mice and a trend toward decreased Bsep expression
was observed in IL10(2/2) mice (Bsep: 69.76 9.5% [DSS] and 77.2
6 8.0% [IL10(2/2)] of controls, P, 0.01 and P, 0.001). Changes
on mRNA level were conﬁrmed by similar ﬁndings for protein
expression in western blotting in DSS-treated mice (see Fig. 3,
Supplemental Digital Content 3, http://links.lww.com/IBD/B317).
Qualitative Changes in Biliary BA Proﬁle in
DSS Mice and IL10(2/2) Mice
To investigate whether these changes in genes involved in
BA homeostasis lead to changes in the composition of murine bile
FIGURE 4. Hepatic target genes of bile acid metabolism. A–D, Relative mRNA expression of IL-6, Fgfr4, Cyp7a1 and Fxr in control, DSS-treated
mice, and IL10(2/2) mice. *P , 0.05, **P , 0.01, ***P , 0.001.
FIGURE 5. Changes in biliary bile acids proﬁle. A–E, Biliary concentrations of total BAs and taurine-conjugated BAs in different mice models are
depicted. *P , 0.05, **P , 0.01, ***P , 0.001.
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concentrations of total BAs, unconjugated BAs and glycine or
taurine-conjugated BAs were determined. In agreement with
previously described results by Jahnel et al23 for DSS mice, no
signiﬁcant change in total BA concentration in gallbladder bile of
DSS-treated mice (58.4 6 7.6 mM) and IL10(2/2) mice (93.7 6
30.8 mM) versus control mice (68.6 6 9.4 mM) was detected
(Fig. 5A). Murine BAs are predominantly conjugated with tau-
rine. In DSS-treated animals, qualitative changes in taurine-
conjugated BA showed a decrease in taurine conjugates such
as tauroursodeoxycholic acid (T-UDCA) (1.18 6 0.18 mM
[control] versus 0.64 6 0.09 mM [DSS]) and taurodeoxy-
cholic acid (T-DCA) (0.74 6 0.17 [control] versus 0.31 6
0.06 mM [DSS], P , 0.05 each). No signiﬁcant difference
was observed in taurine-conjugated BAs for IL10(2/2) mice
(Fig. 5B, C).
Only low levels of glycocholic acid as a glycine-conjugated
BA were measured with a decrease in DSS-treated and IL10(2/2)
mice (0.03 6 0.01 mM [DSS], 0.02 6 0.01 mM [IL10(2/2)]
versus 0.06 6 0.01 mM [control]) (see Fig. 4A, Supplemental
Digital Content 4, http://links.lww.com/IBD/B318). Unconju-
gated BAs showed a trend to decreased concentrations in DSS-
treated and IL10(2/2) mice (see Fig. 4B, Supplemental Digital
Content 4, http://links.lww.com/IBD/B318). Analysis of qualita-
tive changes of free BAs showed signiﬁcantly decreased a- and
b-muricholic acid (M-CA) (as naturally hydrophilic and therefore
less cytotoxic BAs) in the bile of DSS-treated mice (0.31 6
0.17 mM versus 0.17 6 0.08 mM and 0.17 6 0.08 mM versus
0.03 6 0.01 mM, respectively; P , 0.05 each). IL10(2/2) mice
showed a trend toward decreased a-, b-MCA and cholic
acid (CA) (see Fig. 4C–E, Supplemental Digital Content 4,
http://links.lww.com/IBD/B318).
DSS-Treated and IL10(2/2) Mice Have Distinct
Fecal BA Proﬁles
Fecal BA composition as an established effector of
intestinal Fxr/Fgf15 activation was characterized in the same
detail. Interestingly, DSS-treated mice showed changes with
a trend toward decreased total BAs, unconjugated BA, and
signiﬁcant changes in primary (CA and chenodeoxycholic acid
[CDCA]) and secondary BAs such as deoxycholic acid (DCA)
and litocholic acid (LCA) (not signiﬁcant) (Fig. 6A; see Fig. 5B,
Supplemental Digital Content 5, http://links.lww.com/IBD/B319).
No major changes were seen in taurine-conjugated BAs
(Fig. 6B). IL10(2/2) mice showed a signiﬁcant reduction of total
and unconjugated BAs. Free a-MCA, CDCA, ursodeoxycholic
acid (UDCA), Hyo-DCA, LCA, and DCA were signiﬁcantly
reduced in IL10(2/2) mice in contrast to b-muricholic acid,
which was signiﬁcantly increased (Fig. 6A; see Fig. 5A, B,
Supplemental Digital Content 5, http://links.lww.com/IBD/B319).
Interestingly, total taurine-conjugated BAs were signiﬁcantly
increased in IL10(2/2) mice with the highest increase in tauro-b-
MCA (T-b-MCA), T-UDCA, T-CDCA, T-DCA, and T-CA
(Fig. 6B; see Fig. 5A, B, Supplemental Digital Content 5,
http://links.lww.com/IBD/B319).
DISCUSSION
Enterohepatic FGF15/19 signaling is an important pathway
for the regulation of BA metabolism between gut and liver.
Although recent studies have described altered FGF19 serum
levels in patients with IBD, neither the underlying regulatory
events nor the pathophysiological contribution of FGF19 signal-
ing to biliary pathophysiology had been elucidated. To get further
mechanistic insight, we put focus on the analysis of the murine
orthologue of FGF19, that is, Fgf15 signaling and biliary and
fecal BA proﬁle in 2 different IBD mouse models with different
sites of inﬂammation.
Two recent studies showed slightly increased24 or rather
unchanged25 FGF19 serum concentrations in patients with UC
in comparison with healthy controls. Interestingly, however, the
same studies consistently showed that patients with CD had sig-
niﬁcantly lower levels of FGF19 in serum. Patients with the his-
tory of ileal resection had the lowest levels of FGF19 in serum.
This is consistent with the established concept that FGF19 is
mainly expressed in the distal ileum.
In both human studies, serum changes of FGF19 have been
analyzed together with the inﬂammatory site pattern. In this
regard, Lenicek et al25 reported that FGF19 down-regulation only
appeared in cases with a signiﬁcant ileal involvement because CD
patients with Crohn’s colitis had normal FGF19 serum levels and
only those with ileitis had signiﬁcantly decreased FGF19 levels
compared with controls. Consistently, in the study of Iwamoto
et al,24 the only patient with CD and a colonic inﬂammation had
higher FGF19 levels than other CD patients.
In our study, the data derived from 2 different mouse models
show well comparable changes in serum Fgf15 levels: While DSS-
treated mice—as a model of pancolonic inﬂammation sparing the
ileum—had increased Fgf15 mRNA and serum protein levels,
serum Fgf15 tended to be decreased in IL10(2/2) mice that rather
resemble human patients with CD due to the presence of ileal
inﬂammation. In this regard, Fgf15 expression in both our mouse
models nicely reﬂects FGF19 expression in the human clinical
situation. Our ﬁndings therefore strengthen the usefulness of these
mouse models to investigate the signiﬁcance of FGF15/FGF19
signaling for the pathophysiology of human IBD.
Another clinical study in humans analyzed FXR mRNA
levels in the ileum of patients with UC and CD without signiﬁcant
differences at the message level, but interestingly a lower expres-
sion of SHP (as a direct transcriptional target of FXR) was observed
in patients with CD.26 The authors concluded that FXR activity
may be decreased in this subtype of IBD but did not ﬁnd any
association of genetic variation in FXR gene and IBD as the pri-
mary objective of their study.26 In our study, Fgf15 signaling was
activated in DSS-treated mice with a primary inﬂammatory site in
the colon. In contrast, IL10(2/2) mice with inﬂammatory changes in
the complete gastrointestinal tract and also in ileum had a trend
toward lower Fgf15 serum levels, suggesting a putative moderate
decrease of Fxr transactivation activity in this group. Based on our
results and the data derived from the clinical studies cited above, it
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can be hypothesized that ileitis in humans with CD and in IL10(2/2)
mice is consistently characterized by decreased Fxr transactivation
ability that modulates the expression of several Fxr-target genes
including Fgf15.
An interesting question arises with regard to the molecular
mechanism accounting for the alterations observed in the
intestinal Fxr-Fgf15 axis under conditions of ileal inﬂammation.
A recent study has suggested that the gut microbiota plays
a crucial role for the regulation of Fgf15 signaling. Sayin et al27
showed important changes in fecal biliary proﬁle in germ-free
mice. Conventional mice in comparison with germ-free mice
showed an up-regulated expression of Fxr and its target genes
(including Fgf15) in the distal ileum but not in the liver.
Taurine-conjugated a- and b-MCA were identiﬁed as strong Fxr
antagonist in this study with suppressive function of T-b-MCA on
T-CA (Fxr agonist)-treated ileal explants from conventional mice.
Interestingly, germ-free mice showed higher concentrations of
T-b-MCA and T-CA in comparison with conventional mice deﬁn-
ing a molecular basis for the altered expression of gut-speciﬁc Fxr
targets in that study.
With regard to this concept, it is an intriguing ﬁnding of our
study that IL10(2/2) mice are characterized by a signiﬁcant
increase in T-b-MCA in feces. Furthermore, as already described
above, lower Fgf15 serum levels (as well as increased expression
of Asbt as a negative Fxr target gene) were observed in these mice
in comparison with DSS-treated mice. In contrast, DSS-treated
mice had no signiﬁcant changes in fecal T-b-MCA in comparison
with control mice. Together with the data provided by Sayin et al,
our results therefore suggest that one mechanism that contributes
to the pronounced changes of Fxr target gene expression (includ-
ing Fgf15) in the IBD mouse models could rely on the altered
abundance of the potent Fxr antagonists T-a-MCA and T-b-MCA
in the intestine.
In both murine IBD models used in the present study, no
macroscopic changes in liver histology were observed, but an
increase of IL-6 mRNA expression as an indicator of molecular
hepatic inﬂammation with reduced mRNA expression of several
BAs transporters and Cyp7a1 has been detected. This ﬁnding is
well in line with the fact that treatment with recombinant Tnf-a,
IL1-b, or IL-6 in C57BL/6 mice showed a transient or sustained
down-regulation of different hepatic BA transporters such as Ntcp
and Bsep6,28 and Cyp7a1.29 Furthermore, cytokine treatment had
effects on mRNA expression of transcription factors with reduced
Fxr expression after Tnf-a treatment.30 In a recent study, Jahnel
et al23 analyzed hepatic tissue of DSS-treated mice (male BL6
mice received 3% DSS for 7 d) and did not observe any
FIGURE 6. Fecal bile acids proﬁle in mice. A, Changes in total BAs, free Bas, and primary and secondary BAs such as CA, CDCA, and DCA in control,
DSS, and IL10(2/2) mice. B, Taurine-conjugated BAs in the 3 mice groups. *P , 0.05, **P , 0.01, ***P , 0.001.
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functionally relevant changes in hepatocyte gene expression (e.g.,
Cyp7a1, Ntcp, Bsep, Fxr) and bile composition. In contrast to our
study, no change for mRNA expression of inﬂammatory cyto-
kines such as Tnf-a could be observed. Of note, our ﬁndings
are not in contradiction to the study of Jahnel et al23 where no
signs of inﬂammation were found in hepatic tissue of mice using
a different DSS-treatment protocol.
As a hypothesis-building ﬁnding, our study ﬁrstly describes
an inverse regulation of Fgf15 signaling in IBD mouse models
according to the distinct sites of intestinal inﬂammation. Trans-
activation of this pathway was observed in DSS-treated mice
without ileal inﬂammation. In contrast, IL10(2/2) mice with pres-
ent ileitis but absent induction of intestinal Fxr target genes ex-
hibited signiﬁcant changes in fecal BA proﬁle together with high
levels of T-b-MCA as a strong Fxr antagonist. These fuel the
hypothesis that both local inﬂammatory signals and alterations
in fecal BA composition could be an important regulator of the
enterohepatic Fxr-/Fgf15 axis under intestinal inﬂammation.
Whether the observed changes contribute to the development of
cholestatic liver disease in patients with certain site patterns of
inﬂammatory bowel disease remains to be investigated in sub-
sequent studies.
REFERENCES
1. Jahn D, Rau M, Hermanns HM, et al. Mechanisms of enterohepatic ﬁbro-
blast growth factor (FGF) 15/19 signaling in health and disease. Cytokine
Growth Factor Rev. 2015;26:625–635.
2. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology
and therapy. Nat Rev Drug Discov. 2009;8:235–253.
3. Fon Tacer K, Bookout AL, Ding X, et al. Research resource: Compre-
hensive expression atlas of the ﬁbroblast growth factor system in adult
mouse. Mol Endocrinol. 2010;10:2050–2064.
4. Inagaki T, Choi M, Moschetta A, et al. Fibroblast growth factor 15 func-
tions as an enterohepatic signal to regulate bile acid homeostasis. Cell
Metab. 2005;2:217–225.
5. Holt JA, Luo G, Billin AN, et al. Deﬁnition of a novel growth factor-
dependent signal cascade for the suppression of bile acid biosynthesis.
Genes Dev. 2003;17:1581–1591.
6. Goodwin B, Jones SA, Price RR, et al. A regulatory cascade of the nuclear
receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol
Cell. 2000;6:517–526.
7. Lu TT, Makishima M, Repa JJ, et al. Molecular basis for feedback regula-
tion of bile acid synthesis by nuclear receptors. Mol Cell. 2000;6:507–515.
8. Houten SM. Homing in on bile acid physiology. Cell Metab. 2006;4:
423–424.
9. Gadaleta RM, van Mil SW, Oldenburg B, et al. Bile acids and their
nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal
disease. Biochim Biophys Acta. 2010;1801:683–692.
10. Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transport-
ers in normal physiology and liver disease. Gastroenterology. 2004;126:
322–342.
11. Inagaki T, Moschetta A, Lee YK, et al. Regulation of antibacterial defense
in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci
U S A. 2006;103:3920–3925.
12. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis.
Curr Opin Gastroenterol. 2008;24:377–383.
13. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the
induction of reliable experimental acute and chronic ulcerative colitis in
mice. Gastroenterology. 1990;98:694–702.
14. Mahler M, Bristol IJ, Leiter EH, et al. Differential susceptibility of inbred
mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol.
1998;274:G544–G551.
15. Kuhn R, Lohler J, Rennick D, et al. Interleukin-10-deﬁcient mice develop
chronic enterocolitis. Cell. 1993;75:263–274.
16. Leucht K, Caj M, Fried M, et al. Impaired removal of Vbeta8(+) lympho-
cytes aggravates colitis in mice deﬁcient for B cell lymphoma-2-interacting
mediator of cell death (Bim). Clin Exp Immunol. 2013;173:493–501.
17. Martin IV, Schmitt J, Minkenberg A, et al. Bile acid retention and acti-
vation of endogenous hepatic farnesoid-X-receptor in the pathogenesis of
fatty liver disease in ob/ob-mice. Biol Chem. 2010;391:1441–1449.
18. Stieger B, Hagenbuch B, Landmann L, et al. In situ localization of the
hepatocytic Na+/Taurocholate cotransporting polypeptide in rat liver.
Gastroenterology. 1994;107:1781–1787.
19. Madon J, Hagenbuch B, Landmann L, et al. Transport function and
hepatocellular localization of mrp6 in rat liver. Mol Pharmacol. 2000;
57:634–641.
20. Gerloff T, Stieger B, Hagenbuch B, et al. The sister of P-glycoprotein
represents the canalicular bile salt export pump of mammalian liver. J Biol
Chem. 1998;273:10046–10050.
21. Nytofte NS, Serrano MA, Monte MJ, et al. A homozygous nonsense
mutation (c.214C-.A) in the biliverdin reductase alpha gene (BLVRA)
results in accumulation of biliverdin during episodes of cholestasis. J Med
Genet. 2011;48:219–225.
22. Obermeier F, Kojouharoff G, Hans W, et al. Interferon-gamma (IFN-
gamma) and tumor necrosis factor (TNF)-induced nitric oxide as toxic
effector molecule in chronic DSS-induced colitis in mice. Clin Exp Im-
munol. 1999;116:238–245.
23. Jahnel J, Fickert P, Langner C, et al. Impact of experimental colitis on
hepatobiliary transporter expression and bile duct injury in mice. Liver Int.
2009;29:1316–1325.
24. Iwamoto J, Saito Y, Honda A, et al. Bile acid malabsorption deactivates
pregnane X receptor in patients with Crohn’s disease. Inﬂamm Bowel Dis.
2013;19:1278–1284.
25. Lenicek M, Duricova D, Komarek V, et al. Bile acid malabsorption in
inﬂammatory bowel disease: assessment by serum markers. Inﬂamm
Bowel Dis. 2011;17:1322–1327.
26. Nijmeijer RM, Gadaleta RM, van Mil SW, et al. Farnesoid X receptor
(FXR) activation and FXR genetic variation in inﬂammatory bowel dis-
ease. PLoS One. 2011;6:e23745.
27. Sayin SI, Wahlstrom A, Felin J, et al. Gut microbiota regulates bile acid
metabolism by reducing the levels of tauro-beta-muricholic acid, a natu-
rally occurring FXR antagonist. Cell Metab. 2013;17:225–235.
28. Siewert E, Dietrich CG, Lammert F, et al. Interleukin-6 regulates hepatic
transporters during acute-phase response. Biochem Biophys Res Commun.
2004;322:232–238.
29. Merrell MD, Nyagode BA, Clarke JD, et al. Selective and cytokine-
dependent regulation of hepatic transporters and bile acid homeostasis
during infectious colitis in mice. Drug Metab Dispos. 2014;42:596–602.
30. Geier A, Dietrich CG, Voigt S, et al. Cytokine-dependent regulation of
hepatic organic anion transporter gene transactivators in mouse liver. Am J
Physiol Gastrointest Liver Physiol. 2005;289:G831–G841.
Inﬂamm Bowel Dis  Volume 22, Number 10, October 2016 Alterations in Enterohepatic Fgf15 Signaling in IBD
www.ibdjournal.org | 2389
Copyright © 2016 Crohn’s & Colitis Foundation of America, Inc. Unauthorized reproduction of this article is prohibited.
